Innocare Pharma Announces Achievement Of Primary Endpoint In Phase 2B Study Of Orelabrutinib,
Dec 15 (Reuters) - Zenas Biopharma Inc ZBIO.O:
ZENAS BIOPHARMA’S PARTNER, INNOCARE PHARMA, ANNOUNCES ACHIEVEMENT OF PRIMARY ENDPOINT IN PHASE 2B STUDY OF ORELABRUTINIB, A BTK INHIBITOR, FOR SYSTEMIC LUPUS ERYTHEMATOSUS
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.